Inovio Pharmaceuticals, Inc. (INO) Receives Average Rating of “Buy” from Analysts
Shares of Inovio Pharmaceuticals, Inc. (NASDAQ:INO) have earned an average rating of “Buy” from the thirteen brokerages that are currently covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a sell rating, two have assigned a hold rating and nine have assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $19.80.
Several research analysts recently weighed in on INO shares. HC Wainwright restated a “buy” rating and issued a $13.00 price objective on shares of Inovio Pharmaceuticals in a research report on Sunday, May 28th. Maxim Group restated a “buy” rating and issued a $12.00 price objective on shares of Inovio Pharmaceuticals in a research report on Thursday, June 1st. ValuEngine upgraded shares of Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, June 2nd. Piper Jaffray Companies upgraded shares of Inovio Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $14.00 price objective for the company in a research report on Thursday, June 8th. Finally, Zacks Investment Research upgraded shares of Inovio Pharmaceuticals from a “hold” rating to a “buy” rating and set a $8.75 price objective for the company in a research report on Tuesday, July 11th.
Shares of Inovio Pharmaceuticals (NASDAQ:INO) traded down 2.23% during trading on Friday, reaching $6.15. The company’s stock had a trading volume of 976,264 shares. The company’s market capitalization is $554.90 million. Inovio Pharmaceuticals has a 12 month low of $5.28 and a 12 month high of $9.86. The company’s 50-day moving average is $5.73 and its 200-day moving average is $6.65.
Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative net margin of 153.46% and a negative return on equity of 63.67%. The firm had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. During the same quarter in the previous year, the company posted ($0.26) EPS. Inovio Pharmaceuticals’s revenue was up 229.2% on a year-over-year basis. On average, analysts forecast that Inovio Pharmaceuticals will post ($0.92) EPS for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was copied illegally and reposted in violation of United States and international copyright and trademark legislation. The legal version of this story can be accessed at https://www.watchlistnews.com/inovio-pharmaceuticals-inc-ino-receives-average-rating-of-buy-from-analysts/1583606.html.
A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Wasatch Advisors Inc. grew its holdings in shares of Inovio Pharmaceuticals by 43.6% in the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock valued at $20,469,000 after buying an additional 793,306 shares during the period. Vanguard Group Inc. grew its holdings in shares of Inovio Pharmaceuticals by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 3,098,055 shares of the biopharmaceutical company’s stock valued at $20,510,000 after buying an additional 226,861 shares during the period. Candriam Luxembourg S.C.A. acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $1,411,000. GSA Capital Partners LLP acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $1,035,000. Finally, Virtu KCG Holdings LLC acquired a new position in shares of Inovio Pharmaceuticals in the 2nd quarter valued at $556,000. 24.83% of the stock is owned by hedge funds and other institutional investors.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.
Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.